TRAIL and cancer therapy.

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• TRAIL receptors are key targets for selective cancer cell elimination.
• TRAIL-based therapies (proteins, antibodies) demonstrate antitumor activity with few side effects.
• Resistance to TRAIL therapy necessitates combination treatments with sensitizing agents.

Purpose of the Study:

• To provide an overview of the TRAIL signaling pathway.
• To summarize early clinical results of TRAIL therapy.
• To highlight mechanisms of TRAIL resistance and strategies to overcome them.

Main Methods:

• Review of TRAIL signaling pathway.
• Analysis of clinical trial data for TRAIL therapy.
• Discussion of targeted agents to overcome TRAIL resistance.

Main Results:

• TRAIL therapy shows encouraging antitumor effects but frequently encounters resistance.
• Standard chemotherapeutics can enhance TRAIL sensitivity.
• Targeted agents neutralizing apoptotic blockades or suppressing prosurvival signals are effective.

Conclusions:

• TRAIL therapy is a promising cancer treatment strategy.
• Overcoming TRAIL resistance is crucial for maximizing therapeutic potential.
• Targeted agents, including inhibitors of IAPs, Bcl-2 family, HDACi, and modulators of NF-kappaB, Raf, and EGFR, offer effective strategies to enhance TRAIL efficacy.